Oncogene-like addiction to aneuploidy in human cancers.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37410869.
- Also identified by DOI 10.1126/science.adg4521 and PMC identifier 10753973.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most cancers exhibit aneuploidy, but its functional significance in tumor development is controversial. Here, we describe ReDACT (Restoring Disomy in Aneuploid cells using CRISPR Targeting), a set of chromosome engineering tools that allow us to eliminate specific aneuploidies from cancer genomes. Using ReDACT, we created a panel of isogenic cells that have or lack common aneuploidies, and we demonstrate that trisomy of chromosome 1q is required for malignant growth in cancers harboring this alteration. Mechanistically, gaining chromosome 1q increases the expression of <i>MDM4</i> and suppresses p53 signaling, and we show that <i>TP53</i> mutations are mutually exclusive with 1q aneuploidy in human cancers. Thus, tumor cells can be dependent on specific aneuploidies, raising the possibility that these "aneuploidy addictions" could be targeted as a therapeutic strategy.
Medical subject headings
- Cell Cycle Proteins
- Neoplasms
- Oncogenes
- Trisomy
- Gene Editing
- Tumor Suppressor Protein p53